CBDG 财务： THC Farmaceuticals Inc AI 分析

主页

股票

CBDG

财务数据

CBDG 财务

THC Farmaceuticals Inc

$0.04

143.95%

$0.02

收盘价：Apr 02, 16:00:00 GMT-4

$0.04

盘后：Apr 02, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

CBDG 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	09/30/2022	09/30/2021	09/30/2020	09/30/2014	09/30/2013
营收	0	0	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	--
营收成本	0	0	0	0	--	--
毛利润	0	0	0	0	--	--
销售、一般及管理费用	0	0	0	0	0	0
研发	--	--	--	--	--	--
营业费用	0	0	0	0	0	0
其他非经营性收入 (费用)	--	0	0	--	--	--
税前利润	0	0	0	0	0	0
所得税费用	0	--	--	0	0	0
净利润	0	0	0	0	0	0
净利润增长	--	--	--	--	--	--
稀释后流通股数	16.63	18.13	18.13	16.63	8.96	8.96
股份同比变动 (YoY)	--	0%	9%	--	0%	0%
每股收益 (摊薄)	0	0.02	0	0	0	0
每股收益增长率	--	-4,800%	-86%	--	26%	-39%
自由现金流	0	0	0	0	0	0
每股自由现金流	--	--	--	--	--	--
毛利率	0%	0%	0%	0%	--	--
营业利润率	0%	0%	0%	0%	0%	0%
净利率	0%	0%	0%	0%	0%	0%
自由现金流利润率	0%	0%	0%	0%	0%	0%
EBITDA	0	0	0	0	0	0
EBITDA 利润率	0%	0%	0%	0%	0%	0%
EBITDA 中的折旧与摊销	0	0	0	0	0	0
EBIT	0	0	0	0	0	0
EBIT 利润率	0%	0%	0%	0%	0%	0%
有效税率	0%	--	--	0%	0%	0%

Follow-Up Questions

THC Farmaceuticals Inc 的关键财务报表是什么？



根据最新的财务报表（Form-10K），THC Farmaceuticals Inc 的总资产为 $2，净损失为 $0

CBDG 的关键财务比率是什么？



THC Farmaceuticals Inc 的流动比率是 0，净利 margin 为 0，每股销售为 $0。

THC Farmaceuticals Inc 的收入按细分市场或地理位置如何划分？



THC Farmaceuticals Inc 最大收入来源是 Banking and Related Activities，在最近的收益报告中收入为 8,603,553。就地区而言， United States 是 THC Farmaceuticals Inc 的主要市场，收入为 8,603,553。

THC Farmaceuticals Inc 是否盈利？



不，根据最新的财务报表，THC Farmaceuticals Inc 的净损失为 $0

THC Farmaceuticals Inc 有负债吗？



不，THC Farmaceuticals Inc 的负债为 0

THC Farmaceuticals Inc 的流通股有多少？



THC Farmaceuticals Inc 的总流通股为 16.63

关键数据

前收盘价

$0.0182

开盘价

$0.02

当日区间

$0.02 - $0.0444

52周范围

$0.0033 - $0.1

交易量

1.0K

平均成交量

294

股息收益率

每股收益（TTM）

-0.00

市值

$804.9K

什么是 CBDG？

THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona and currently employs 2 full-time employees. The company went IPO on 2012-08-22. The firm specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. The company offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The firm owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. The company offers a network of micro vending kiosk systems.

功能特性

资源